Science
Publications and Posters
Belumosudil (KD025) and cGVHD
- 8/29/2020BELUMOSUDIL (KD025) For Patients with Chronic Graft Versus Host Disease (cGVHD): Long Term Follow Up of a Phase 2A Study (KD025 208). European Society for Blood and Bone Marrow Transplantation. 2020.
View - 8/29/2020Analysis of the ROCKstar Study: A Phase 2, Randomized, Multi-center Study to Evaluate the Efficacy and Safety of BELUMOSUDIL (KD025) in Subjects With cGVHD. European Society for Blood and Bone Marrow Transplantation. 2020.
View - 5/27/2020Presentation and Management of cGVHD in Real-World Clinical Practice: A Medical Chart Audit. European Hematology Association. 2020.
View - 2/23/2020Interim Analysis of KD025-213: A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) after at Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study). Transplantation and Cellular Therapy Meetings. 2020.
View - 2/19/2020KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) Long-term Follow-up of a Phase 2a Study (KD025-208). Transplantation and Cellular Therapy Meetings. 2020.
View - 12/9/2019Epidemiology and Real-World Treatment of Chronic Graft-Versus-Host Disease Post Allogeneic Hematopoietic Cell Transplantation (HCT): A U.S. Claims Analysis. ASH Annual Meeting and Exposition. 2019.
View
Immuno-oncology: IL-15 Fusion Protein Platform
- 2/5/2021Single-Dose Anti PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory Responses. Molecular Cancer Therapeutics. 2021.
View - 11/11/2020A novel human anti-PD1/IL15 bi-functional protein with robust anti-tumor activity and low systemic toxicity. The Society for Immunotherapy of Cancer. 2020.
View - 6/24/2020Anti-PD-L1/IL15 fusion protein KD033 demonstrated efficient T cell redirected killing of PD-L1 expressing target cells and in vivo efficacy that correlated to its retention in tumors. American Association for Cancer Research. 2020.
View - 6/24/2020A novel anti-PD1-IL-15 immunocytokine potentiates anti-tumor T cell activity of PD-1 checkpoint blockade and IL-2/15R-beta-gamma agonism. American Association for Cancer Research. 2020.
View - 12/12/2019Anti-PDL1/IL-15 fusion protein increases efficacy-associated rare effector cells in cynomolgus monkey and mouse peripheral blood. European Society for Medical Oncology. 2019.
View - 11/1/2019Synergistic efficacy of anti-PD-L1/IL-15 fusion protein in combination with anti-CTLA-4 antibody in a murine orthotopic 4T1 breast carcinoma model. Society for Immunotherapy of Cancer. 2019.
View
ROCK Inhibition
- 1/14/2018Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10. The Journal of Immunology. 2018.
Read More - 6/19/2016ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings. Sci. Signal. 2016.
Read More - 6/16/2016
- 4/28/2016Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016.
Read More - 4/1/2015
- 11/25/2014Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. PNAS. 2014.
Read More - 1/1/2014